Pluri Inc (PLUR) Q1 2025 Earnings Report

Pluri Inc reported its QQ1 2025 results with a modest top line of $0.326 million and a gross margin of 61.3%, yet a substantial operating loss of $5.701 million and a net loss of $5.882 million. R&D spending remained the dominant driver of expense at $3.392 million, with G&A of $2.509 million, contributing to a total operating expense of $5.901 million. The quarter’s EBITDA was negative $5.754 million, with an operating margin of -17.5%. The company burned cash from operating activities by $4.064 million, generating a negative free cash flow of $4.272 million for QQ1 2025. On the balance sheet, Pluri carried roughly $30.9 million in total debt against liquid assets totaling about $25.7 million (cash and short-term investments), and posted a negative stockholders’ equity of approximately -$5.28 million. Despite the losses, the current liquidity position appears adequate on a short-term basis, as the reported current ratio stood at 5.90x, supported by a sizable cash and investment balance. The company’s strategic focus remains on placental-derived cell therapies, notably PLXPAD (Phase III for hip fracture muscle recovery; Phase II for ARDS) and PLXR18 for incomplete hematopoietic recovery, among others. A key near-term message for investors is that financial improvement hinges on meaningful pipeline advancement and potential monetization via licensing or partnerships, given the heavy R&D burn and the need for additional capital to sustain operations if near-term milestones are not met.